Examining the circulating NK cells in patients at different stages of disease revealed similar numbers of CD56+ NK cells at all stages (Figure 2A), however there was lower expression of CD16/FcγRIII on NK cells from later stage NSCLC patients, with more CD56+ CD16+ cells found amongst stage I-IVA NSCLC patients (p=0.018; Figure 1B, 2A–C). Here, NCAM1 is linked to non-small cell lung carcinoma.